YH32367, a novel HER2/4-1BB bispecific antibody (BsAb), simultaneously targets HER2 and h4-1BB and binds to both targets. YH32367 exhibits a strong 4-1BB signal activation as well as blocking of HER signaling in HER2-expressing tumor cells. YH32367 stimulats IFN-γ secretion from T cells and thereby inducing tumor cells lysis.~This is a Phase 1/2, non-randomized, open-label, multicenter, first-in-human study of YH32367. This 2-part study will include both a Dose Escalation part, to identify the Maximum Tolerated Dose (MTD) or the RP2D of YH32367, and a Dose Expansion part, to confirm the safety, tolerability and efficacy of YH32367 at the RP2D.
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.